MetaADEDB 2.0 @ LMMD
Insulin Lispro
(WNRQPCUGRUFHED-DETKDSODSA-N)
Structure
SMILES
NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(=O)N)CS)Cc1ccc(cc1)O)CC(=O)N)CCC(=O)O)CC(C)C)CCC(=O)N)Cc1ccc(cc1)O)CC(C)C)CO)CS)[C@H](CC)C)CO)[C@H](O)C)CS)CS)CCC(=O)N)CCC(=O)O)C(C)C)[C@H](CC)C.NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)[C@H](O)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc1ccccc1)N)CC(=O)N)CCC(=O)N)Cc1cnc[nH]1)CC(C)C)CS)CO)Cc1cnc[nH]1)CC(C)C)CCC(=O)O)C)CC(C)C)Cc1ccc(cc1)O)CC(C)C)CS)CCC(=O)O)CCCNC(=N)N)Cc1ccccc1)Cc1ccc(cc1)O
Molecular Formula:
C257H389N65O77S6
Molecular Weight:
5813.620
Log P:
5.2162
Hydrogen Bond Acceptor:
146
Hydrogen Bond Donor:
84
TPSA:
2531.87
CAS Number(s):
N/A
Synonym(s)
1.
Insulin Lispro
2.
28(B)-Lys-29(B)-Pro-Insulin
3.
28(B)-Lysine-29(B)-Prolineinsulin
4.
Humalog
5.
Humalog Kwikpen
6.
Insulin, Lys(28B)-Pro(29B)-
7.
Insulin, Lysyl(28B)-Prolyl(28B)-
8.
LYSPRO
9.
Lispro
10.
Kwikpen, Humalog
11.
Lispro, Insulin
External Link(s)
MeSHD061268
PubChem Compound16132438
Therapeutic Target DatabaseD0L6JE
D03YLE
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Blood glucose increasedFAERS: 44
Canada Vigilance: 14		Canada Vigilance
US FAERS
2Incorrect dose administeredFAERS: 11
Canada Vigilance: 1		Canada Vigilance
US FAERS
3Blood glucose decreasedFAERS: 9
Canada Vigilance: 1		Canada Vigilance
US FAERS
4Maternal exposure during pregnancyFAERS: 8US FAERS
5Drug dose omissionFAERS: 6US FAERS
6Drug ineffectiveFAERS: 6
Canada Vigilance: 20		Canada Vigilance
US FAERS
7Visual ImpairmentFAERS: 6US FAERS
8Blood glucose fluctuationFAERS: 5US FAERS
9CataractFAERS: 5US FAERS
10PruritusFAERS: 5US FAERS
11Blood glucose abnormalFAERS: 4
Canada Vigilance: 5		Canada Vigilance
US FAERS
12PainFAERS: 4US FAERS
13Weight decreasedFAERS: 4US FAERS
14Cerebrovascular accidentFAERS: 3US FAERS
15FatigueFAERS: 3US FAERS
16Feeling abnormalFAERS: 3US FAERS
17Incorrect product storageFAERS: 3US FAERS
18Injection site painFAERS: 3US FAERS
19Injury associated with deviceFAERS: 3US FAERS
20MalaiseFAERS: 3US FAERS
21Medication ErrorFAERS: 3US FAERS
22Accidental exposure to productFAERS: 2US FAERS
23ArthralgiaFAERS: 2US FAERS
24DizzinessFAERS: 2US FAERS
25FormicationFAERS: 2US FAERS
26Incorrect route of drug administrationFAERS: 2US FAERS
27KetoacidosisFAERS: 2US FAERS
28KetosisFAERS: 2US FAERS
29Multiple SclerosisFAERS: 2US FAERS
30Musculoskeletal chest painFAERS: 2US FAERS
31NasopharyngitisFAERS: 2US FAERS
32NauseaFAERS: 2US FAERS
33Pharyngeal swellingFAERS: 2US FAERS
34Suicide attemptFAERS: 2US FAERS
35TremorFAERS: 2US FAERS
36VertigoFAERS: 2US FAERS
37VomitingFAERS: 2US FAERS
38Ankle FractureFAERS: 1US FAERS
39ArthritisFAERS: 1US FAERS
40BlindnessFAERS: 1US FAERS
41Blood cholesterol increasedFAERS: 1US FAERS
42BradyphreniaFAERS: 1US FAERS
43Burning sensationFAERS: 1US FAERS
44CellulitisFAERS: 1US FAERS
45Cold sweatFAERS: 1US FAERS
46Completed SuicideFAERS: 1US FAERS
47ConstipationFAERS: 1US FAERS
48DiscomfortFAERS: 1US FAERS
49Drug prescribing errorFAERS: 1US FAERS
50DysgeusiaFAERS: 1US FAERS
51ErythemaFAERS: 1US FAERS
52Expired product administeredFAERS: 1US FAERS
53FlushingFAERS: 1US FAERS
54Foaming at mouthFAERS: 1US FAERS
55GlaucomaFAERS: 1US FAERS
56Inappropriate schedule of drug administrationFAERS: 1US FAERS
57InfectionFAERS: 1US FAERS
58InfluenzaFAERS: 1US FAERS
59Insulin ResistanceFAERS: 1US FAERS
60Joint swellingFAERS: 1US FAERS
61Lip swellingFAERS: 1US FAERS
62Lower respiratory tract infectionFAERS: 1US FAERS
63Maternal exposure during breast feedingFAERS: 1US FAERS
64Maternal exposure timing unspecifiedFAERS: 1US FAERS
65Middle insomniaFAERS: 1US FAERS
66NephrolithiasisFAERS: 1US FAERS
67NeuroglycopeniaFAERS: 1US FAERS
68No adverse eventFAERS: 1US FAERS
69OsteomyelitisFAERS: 1US FAERS
70Peripheral swellingFAERS: 1US FAERS
71PneumoniaFAERS: 1US FAERS
72Product dose omissionFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
73PsoriasisFAERS: 1US FAERS
74Pulmonary sepsisFAERS: 1US FAERS
75SclerodermaFAERS: 1US FAERS
76SepsisFAERS: 1US FAERS
77Skin UlcerFAERS: 1US FAERS
78SwellingFAERS: 1US FAERS
79Therapeutic product effect variableFAERS: 1US FAERS
80Unevaluable eventFAERS: 1US FAERS
81Unresponsive to stimuliFAERS: 1US FAERS
82Urine ketone bodyFAERS: 1US FAERS
83Wrong doseFAERS: 1US FAERS
84Wrong patient received medicationFAERS: 1US FAERS
85Diabetes mellitus inadequate controlCanada Vigilance: 1Canada Vigilance
86Incorrect route of product administrationCanada Vigilance: 1Canada Vigilance
87LymphomaCanada Vigilance: 1Canada Vigilance
88Memory impairmentCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120236

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.